Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 3/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22940000 | 1.00 | LMNA (0.38) | LMNACCNE1CDK2CCNT1CDK1 | |
| Hydrochloric Acid SCHEMBL16341570 | 0.98 | LMNA (0.37) | LMNACCNE1CDK2CCNT1CDK1 | |
| SCHEMBL4870076 | 0.98 | LMNA (0.39) | LMNACCNE1CDK2CCNT1CDK1 | |
| SCHEMBL21577450 | 0.86 | KCNH2 (0.34) | LMNAADORA2A | |
| SCHEMBL27963399 | 0.75 | LMNA (0.35) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL12903263 | 0.74 | CCNE1 (0.46) | CCNE1CDK2CCNT1CDK1CDK4 | |
| SCHEMBL11015922 | 0.74 | KDM4E (0.40) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9442396 | 0.74 | PI4KA (0.37) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3237878 | 0.74 | PI4KA (0.37) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4964108 | 0.74 | KDM4E (0.40) | LMNAPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007004165-A2 | PROCESS FOR THE PREPARATION OF PERINDOPRIL | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-11 | — | — | WO | claimed |
| CN-105683178-B | triazine derivatives | 卡尔那生物科学株式会社 | 2019-04-12 | — | — | CN | disclosed |
| EP-2542532-B1 | METHOD FOR PREPARING CARBENE IN SOLUTION AND STABLE FORM OF CARBENE OBTAINED BY SAID METHOD | BLUESTAR SILICONES FRANCE (FR) | 2018-01-03 | — | — | EP | disclosed |
| EP-1306131-B1 | Cross-coupling process using a catalyst comprising a cyclic nitrogen ligand | SUMITOMO CHEMICAL CO (JP) | 2016-12-07 | — | — | EP | disclosed |
| EP-2542532-A1 | METHOD FOR PREPARING CARBENE IN SOLUTION, NOVEL STABLE FORM OF CARBENE OBTAINED IN PARTICULAR BY MEANS OF SAID METHOD, AND USES THEREOF IN CATALYSIS | Bluestar Silicones France SAS (FR) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011083146-A1 | METHOD FOR PREPARING CARBENE IN SOLUTION, NOVEL STABLE FORM OF CARBENE OBTAINED IN PARTICULAR BY MEANS OF SAID METHOD, AND USES THEREOF IN CATALYSIS | BLUESTAR SILICONES FRANCE SAS (FR) | 2011-07-14 | — | — | WO | disclosed |
| WO-2007004165-A2 | PROCESS FOR THE PREPARATION OF PERINDOPRIL | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-11 | — | — | WO | disclosed |
| US-20060111593-A1 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2006-05-25 | — | — | US | disclosed |
| US-7041856-B2 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-05-09 | — | — | US | disclosed |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
| US-6960601-B2 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
| US-20030162950-A1 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-08-28 | — | — | US | disclosed |
| EP-1306131-A2 | Cross-Coupling catalyst comprising a cyclic nitrogen ligand and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162950-A1 | Coupling catalyst and process using the same | NOD1, PYM1, C9 | LMNA 1888/4885CCNE1 526/4885CDK2 673/4885 |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | LMNA 4010/4885CCNE1 3647/4885CDK2 1398/4885 |
| US-20060111593-A1 | Coupling catalyst and process using the same | RPL22, C9, RBM22 | LMNA 1071/4885CCNE1 404/4885CDK2 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.